Pioneering Genetic Therapies for Duchenne Muscular Dystrophy

Mission

At ART BioScience we are committed to the development of a new class of therapeutics based on messenger RNA (mRNA) for the treatment of Orphan diseases, primarily Duchenne Muscular Dystrophy

Vision

To be recognized as a leader in the discovery, development and commercialization of novel mRNA therapeutics by leveraging a deep understanding of Duchenne biology, specifically strengthening the musculoskeletal system. 

Focus

Genetic musculoskeletal system disorders

art bioscience.png

Treat Orphan Diseases,

Primarily Duchenne Muscular Dystrophy

Leadership

Our leadership team has deep and diverse industry knowledge, a passion for science and innovation, and we consistently push the boundaries of scientific excellence and discovery in order to transform lives.

Pipeline

We are advancing innovative mRNA genetic therapeutics for Duchenne Molecular Dystrophy using our proprietary Nano Lipid Particles  delivery system

Blue Pathway